Navigation Links
Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
Date:2/2/2012

LA JOLLA, Calif. -- The National Cancer Institute (NCI) estimates that as many as one in 51 men and women will be diagnosed with melanomathe deadliest form of skin cancerat some point during their lifetimes. A research team led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) is working to unravel the molecular mechanisms underlying the development and progression of this disease in hopes of improving prevention and treatment strategies. To do this, Ronai's laboratory has been studying a protein named Activating Transcription Factor 2 (ATF2), which is associated with poor prognosis in melanoma. ATF2 is a two-faced proteinin melanoma cells, it's oncogenic, or cancer-causing, while in non-malignant types of skin cancers, it acts as a tumor suppressor. In a paper published February 3 in the journal Cell, the team identified a molecular switch that controls ATF2's dual functions. This switch is controlled by protein kinase Cε (PKCε), which disables ATF2's tumor-suppressing activities, sensitizing cells to chemotherapy; instead, ATF2's tumor-promoting activity is enhanced. The team also found that high levels of PKCε in melanoma are associated with poor prognosis.

"PKCε is the culprit behind melanoma's 'oncogenic addiction,'" said Ronai, associate director of the Sanford-Burnham's NCI-designated Cancer Center and senior author of the study. "ATF2 is normally a 'good guy.' But when there is too much PKCεas in malignant melanomaATF2 becomes an oncogene, promoting tumor development."

In this study, Ronai and lead author Eric Lau, Ph.D., a postdoctoral researcher in his lab, found that PKCε's malignant power is in its ability to direct ATF2's location and activity within a cell. In a normal cell, PKCε modifies ATF2, keeping it in the nucleus, where it turns genes on and off and helps repair damaged DNA. When the cell experiences exposure to toxicity or stress (radiation,
'/>"/>

Contact: Heather Buschman, Ph.D.
hbuschman@sanfordburnham.org
858-795-5343
Sanford-Burnham Medical Research Institute
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
2. Dr. Kristiina Vuori Promoted to President of Sanford-Burnham Medical Research Institute
3. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
4. Researchers Spot Potential Bile Duct Cancer Drug Targets
5. Georgetown Lombardi researchers present new findings on head & neck cancers
6. Researchers discover method to unravel malarias genetic secrets
7. Researchers quantify muscle soreness
8. Georgetown professor applauds decision of researchers to temporarily halt research on H5N1
9. Health benefits of exercise may depend on cellular degradation, UT Southwestern researchers report
10. Autism redefined: Yale researchers study impact of proposed diagnostic criteria
11. University of Tennessee researchers develop comprehensive, accessible vision testing device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sanford-Burnham researchers find molecular switch that allows melanoma to resist therapy
(Date:6/17/2013)... NY (June 17, 2013) A team from the ... the Naomi Berrie Diabetes Center of Columbia University has ... reflect the features of maturity-onset diabetes of the young ... MODY patients to produce induced pluripotent stem (iPS) cells, ... a mouse, the stem cell-derived beta cells secreted insulin ...
(Date:6/17/2013)... 17, 2013 The Professional Center ... they are now open in Schertz. The ... counseling and access to educational support groups. , ... used to help with athletic performance, post traumatic ... center, Cheryl Camarillo, LCSW, works primarily with those ...
(Date:6/17/2013)... Pa. (PRWEB) June 17, 2013 Without ... worldwide is expected to almost double by 2025 to ... to join together to advance research for the debilitating ... innovative initiatives hold hope for a promising future in ... in research, focus on much-needed support for caregivers and ...
(Date:6/17/2013)... Toronto, Ontario (PRWEB) June 17, 2013 Reliable ... as it helps in having an internet portal that can ... to consider when they are executing their duties. Collecting fees ... if it is not carried out efficiently. In such cases, ... can ensure that the task can be carried out efficiently ...
(Date:6/17/2013)... 17, 2013 Registered Dietitian and Founder ... article today on Tatalou.com outlining her four ways to ... Tricks to Improve Memory ,” includes the benefits of ... video games. , Chevreau also introduces the importance ... in Brain Clarity, a product Chevreau created specifically ...
Breaking Medicine News(10 mins):Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 2Health News:NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes 3Health News:Professional Center for Enhanced Performance Opens in Schertz 2Health News:World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting 2Health News:World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting 3Health News:World Leaders in Alzheimer’s Innovation to Discuss Progress, Collaboration at DIA Annual Meeting 4Health News:PayCanada Offers Link to Pay Services to its Customers 2Health News:4 Tricks to Improve Memory for Women 2
... Merit Medical,Systems, Inc. (Nasdaq: MMSI ), a ... in cardiology and radiology,procedures, announced today that the Company ... year ended December 31, 2007, after the,close of the ... will hold its investor conference call on the same ...
... Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" or ... Republic of China ("PRC"), today,announced that Enze ... of Lotus, has implemented cost saving strategies, ... by approximately 50%., The environmentally-friendly strategies ...
... run on both conventional gasoline and stored electricity ... until more sustainable technology is developed, according to ... International Journal of Automotive Technology and Management, they ... slow development of more sustainable fuel-cell powered electric ...
... China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. ... Company"), a leading manufacturer and distributor of ... announced its CFO,Mr. Yizhao Zhang, will present ... Growth,Stock Conference in Dana Point, California., ...
... Moratorium on Bisphenol,A in Baby Bottles, Food and Beverage ... of state,and national environmental health organizations in the U.S. ... use of bisphenol A (BPA) in baby,bottles and other ... a,new study that demonstrates the toxic chemical BPA leaches ...
... 60 Percent Less ... Calories and Sugar, YUBA CITY, Calif., ... Growers Inc. has introduced,PlumSmart Light, a lower calorie version of the popular ... 11 grams of,sugar, PlumSmart Light is a delicious and fresh way to ...
Cached Medicine News:Health News:Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Year Ended December 31, 2007 2Health News:Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Year Ended December 31, 2007 3Health News:Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies 2Health News:The trouble with hybrids 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Conference 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Conference 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4Health News:Sunsweet Introduces PlumSmart Light(R) 2
(Date:6/17/2013)... NEWPORT BEACH, Calif. , June 17, 2013 /PRNewswire-iReach/ ... healthcare financing options for consumers, including gastric bypass and ... hired additional staff in order to effectively contact as ... services. The increase in staff is all part of ... in order to assist patients with both good and ...
(Date:6/17/2013)... DEERFIELD, Ill. and OSAKA, Japan ... Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals ... NESINA (alogliptin) and the fixed-dose combination therapies KAZANO (alogliptin ... now available by prescription in pharmacies in ... approved by the U.S. Food and Drug Administration (FDA) ...
(Date:6/17/2013)... YORK , June 14, 2013 The law ... just commenced what is believed to be the first suit ... of pancreatic cancer in the user of two common anti-diabetic ... by Staten Island resident Robert ... Amylin Pharmaceuticals, LLC, et al., E.D.N.Y. CV 13-3411. ...
Breaking Medicine Technology:United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services 2United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet 2
... (ERT), (Nasdaq: ERT ) a global ... to biopharmaceutical and healthcare organizations and the market leader ... in drug development, announced today results for the ... noted, all comparative numbers refer to changes from ...
... MOUNTAIN VIEW, Calif., Aug. 1, 2011 VIVUS, Inc. ... development and commercialization of novel therapeutic products, today reported its financial ... 2011. Second Quarter ResultsFor the second quarter ... million, or $0.20 per share, as compared to a net loss ...
Cached Medicine Technology:ERT Reports Second Quarter 2011 Operating Results 2ERT Reports Second Quarter 2011 Operating Results 3ERT Reports Second Quarter 2011 Operating Results 4ERT Reports Second Quarter 2011 Operating Results 5ERT Reports Second Quarter 2011 Operating Results 6ERT Reports Second Quarter 2011 Operating Results 7ERT Reports Second Quarter 2011 Operating Results 8ERT Reports Second Quarter 2011 Operating Results 9ERT Reports Second Quarter 2011 Operating Results 10ERT Reports Second Quarter 2011 Operating Results 11ERT Reports Second Quarter 2011 Operating Results 12ERT Reports Second Quarter 2011 Operating Results 13VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 2VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 3VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 4VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 5VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 6VIVUS Reports Second Quarter and First Six Months 2011 Financial Results 7
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from ...
Ideal for abdominal and flank procedures....
Male high waisted compression girdle with CDIs Wonderfabric™...
CDIs 2nd Stage Abdominoplasty Girdle - a feminine, easy pull-on version of the 8000 series...
Medicine Products: